|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.75 - 2.75|
|52 Week Range||2.16 - 5.48|
|PE Ratio (TTM)||0.70|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Hema Diagnostic Systems, LLC dba NuGenerex Diagnostics (www.hemadiagnosticsystems.com), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), announced today the filing of a patent on its new diagnostic qualitative point-of-care platform, the Express II. Analytes that can be measured by this new device include antigens or antibodies and protein biomarkers which are found in infectious diseases, metabolic diseases and in a host of other medical conditions. The Express II has major advantages over other point-of-care devices because of its simplicity of use, which include fewer steps of operation, the elimination of loops or pipettes for transferring samples, the elimination of unnecessary sample pickup pads, and its ability to be utilized in professional settings, remote field use and for individual in-home use directly by consumers who can conduct the test by themselves in privacy.
Generex Biotechnology Corporation (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased and proud to announce that Terry Thompson has joined the Company’s executive management team as Chief Operating Officer to lead the Company’s efforts in building an end-to-end solution for patients, to include pharmacy, clinical laboratories, pharmacogenomic testing (PGx), compounding, drug manufacturing, and other ancillary health management services. Mr. Thompson brings a wealth of experience and expertise in healthcare, providing executive leadership in pharmacy benefits management, network administration, claims processing, and distribution & logistics for drugs, durable medical equipment (DME), and infusion therapy, as illustrated by his impressive 35-year career.
Generex Biotechnology Corporation today issued the following letter from the Company’s President & Chief Executive Officer, Joseph Moscato, providing his fellow stockholders with a summary of the Company’s initiatives and achievements over the course of 2017.
Generex Biotechnology Corporation today announced the following access information for its investor conference call, to be hosted by President & Chief Executive Officer Joseph Moscato, and his management team, tomorrow, Thursday, January 4, 2018, at 10:30 a.m.
Generex Biotechnology Corporation today announced that it has completed the acquisition of two pre-operational retail pharmacy operations.
Generex Biotechnology Corporation today confirmed its receipt of the $700,000 USD up-front license fee payable by Shenzhen BioScien Pharmaceuticals Co.
Generex Biotechnology Corporation today announced that it will hold an investor conference call at 10:30 a.m.
Generex Biotechnology Corporation today announced that its wholly-owned subsidiary, Antigen Express, Inc.
Generex Biotechnology Corporation today announced that trading in its common stock will be upgraded to the OTCQB® Venture Market on November 30, 2017 after a successful application to up-list from the OTC Pink Market.
Generex Biotechnology Corporation today announced the results of the annual meeting of the Company’s stockholders held on November 21, 2017.
Generex Biotechnology Corporation today announced that its subsidiary, Hema Diagnostic Systems, LLC , has entered into an exclusive contract with Imerlab Sociedad Comercial Limitada for the distribution and sale of the Rapid 1-2-3® Hema HIV EXPRESS® diagnostic test in the Republic of Chile.
Generex Biotechnology Corporation today announced the participation by its subsidiary, Hema Diagnostic Systems LLC , in a diagnostic clinical trial for tuberculosis in Sub-Saharan African countries.
Generex Biotechnology Corporation today announced that its subsidiary, Hema Diagnostic Systems LLC , has received an initial order for its Rapid 1-2-3® Hema HIV EXPRESS® from Diagnostiko Ltda.
Generex Biotechnology Corporation today provided the following summary of the Ii-Key Hybrid Vaccine Platform under development by its wholly-owned subsidiary, Antigen Express, Inc.
Generex Biotechnology Corporation today announced that its wholly-owned subsidiary, Antigen Express, Inc. has entered into a clinical trial collaboration agreement with Merck , through a wholly-owned subsidiary, to evaluate Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® , in patients with metastatic triple-negative breast cancer.